UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2023

 

Commission File Number: 001-36515

 

 

Materialise NV

 

 

Technologielaan 15

3001 Leuven

Belgium

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x            Form 40-F  ¨

 

This Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-213649).

 

 

 

 

 

 

Third Quarter 2023 Financial Results

 

Except as otherwise required by the context, references to “Materialise,” “Company,” “we,” “us” and “our” are to Materialise NV and its subsidiaries.

 

Third Quarter 2023 Results

 

Total revenue for the third quarter of 2023 increased 3.2% to 60,130 kEUR from 58,288 kEUR for the third quarter of 2022.

 

Revenue from our Materialise Software segment was 10,811 kEUR for the third quarter of 2023 compared to 10,863 kEUR for the same quarter last year.

 

Revenue from our Materialise Medical segment increased by 13.4% to 24,263 kEUR for the third quarter of 2023 compared to 21,391 kEUR for the same period in 2022.

 

Revenue from our Materialise Manufacturing segment decreased 3.8% to 25,056 kEUR for the third quarter of 2023 from 26,033 kEUR for the third quarter of 2022.

 

Gross profit was 33,696 kEUR compared to 32,042 kEUR for the same period last year, while gross profit as a percentage of revenue increased to 56.0% compared to 55.0% for the third quarter of 2022.

 

Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses decreased, in the aggregate, 4.2% to 32,076 kEUR for the third quarter of 2023 from 33,491 kEUR for the third quarter of 2022.

 

Net other operating income decreased to 710 kEUR from 1,166 kEUR for the third quarter of 2022.

 

Operating result amounted to 2,330 kEUR compared to (282) kEUR for the third quarter of 2022.

 

Net financial result was 1,319 kEUR compared to 2,173 kEUR for the third quarter of 2022.

 

The third quarter of 2023 contained income tax results of 363 kEUR compared to (478) kEUR in the third quarter of 2022.

 

As a result of the above, net profit for the third quarter of 2023 was 4,013 kEUR, compared to 1,413 kEUR for the same period in 2022. Total comprehensive income for the third quarter of 2023, which includes exchange differences on translation of foreign operations, was 3,242 kEUR compared to 1,638 kEUR for the corresponding 2022 period.

 

At September 30, 2023, we had cash and cash equivalents of 133,953 kEUR, compared to 140,867 kEUR at December 31, 2022. Gross debt amounted to 66,222 kEUR compared to 80,980 kEUR at December 31, 2022. As a result, our net cash position (cash and cash equivalents less gross debt) was 67,731 kEUR compared to 59,887 kEUR at December 31, 2022.

 

Cash flow from operating activities for the third quarter of the year 2023 was 8,143 kEUR, compared to 3,840 kEUR for the same period in 2022. Total capital expenditures for the third quarter of 2023 amounted to 3,920 kEUR.

 

Net shareholders’ equity at September 30, 2023 was 236,631 kEUR compared to 228,928 kEUR at December 31, 2022.

 

Adjusted EBITDA amounted to 7,857 kEUR for the third quarter of 2023, a 55% increase compared to 5,072 kEUR for the corresponding 2022 period. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the third quarter of 2023 was 13.1% compared to 8.7% for the third quarter of 2022.

 

Adjusted EBITDA from our Materialise Software segment increased significantly to 1,781 kEUR from 202 kEUR while the segment Adjusted EBITDA margin (segment Adjusted EBITDA divided by segment revenue) was 16.5% compared to 1.9% for the corresponding prior-year period.

 

 

 

 

Adjusted EBITDA from our Materialise Medical segment increased by 50% to 7,143 kEUR for the third quarter of 2023 compared to 4,765 kEUR while the segment Adjusted EBITDA margin was 29.4% compared to 22.3% for the third quarter of 2022.

 

Adjusted EBITDA from our Materialise Manufacturing segment amounted to 1,074 kEUR compared to 2,530 kEUR for the same period last year, while the segment Adjusted EBITDA margin was 4.3% compared to 9.7% for the third quarter of 2022.

 

Non-IFRS Measures

 

Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

 

Exchange Rate

 

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.0594, the reference rate of the European Central Bank on September 30, 2023.

 

Other Information

 

Brigitte de Vet-Veithen, our current Executive Vice President of Material Medical, has been named our new Chief Executive Officer, effective January 1, 2024. Mrs. de Vet-Veithen will succeed Fried Vancraen, who co-founded Materialise in 1990 and has served as our Chief Executive Officer for 33 years. As of January 1, 2024, Mr. Vancraen will continue to represent Materialise as the new non-executive Chairman of our Board of Directors (the “Board”). In this new role, Mr. Vancraen will succeed Peter Leys, who has been the Executive Chairman of the Board for 10 years and will continue as a member of the Board. Further, as of January 1, 2024, co-founder Hilde Ingelaere will step back from her role as Executive Vice President, but will continue to serve on the Board. Our Executive Committee will continue its strategic and operational role under the new presidency of Mrs. de Vet-Veithen.

 

Biographical information for Mrs. de Vet-Veithen, Mr. Vancraen, Mr. Leys and Mrs. Ingelaere may be found in “Item 6. Directors, Senior Management and Employees” in our Annual Report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission on April 18, 2023.

 

About Materialise

 

Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world.

 

 

 

 

Consolidated income statements (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In '000  2023   2023   2022   2023   2022 
   U.S.$             
Revenue   63,702    60,130    58,288    190,832    169,319 
Cost of Sales   (28,005)   (26,435)   (26,245)   (83,249)   (76,236)
Gross Profit   35,697    33,696    32,042    107,583    93,083 
Gross profit as % of revenue   56.0%   56.0%   55.0%   56.4%   55.0%
                          
Research and development expenses   (10,039)   (9,476)   (9,313)   (27,982)   (26,074)
Sales and marketing expenses   (14,789)   (13,960)   (15,198)   (42,418)   (44,841)
General and administrative expenses   (9,153)   (8,640)   (8,980)   (27,213)   (26,089)
Net other operating income (expenses)   753    710    1,166    (3,238)   2,603 
Operating (loss) profit   2,469    2,330    (282)   6,732    (1,318)
                          
Financial expenses   (1,646)   (1,554)   (2,110)   (3,599)   (4,671)
Financial income   3,043    2,873    4,283    4,987    9,800 
Share in loss of joint venture   -    -    -    -    - 
(Loss) profit before taxes   3,866    3,649    1,891    8,120    3,812 
                          
Income Taxes   385    363    (478)   (886)   (1,377)
Net (loss) profit for the period   4,251    4,013    1,413    7,234    2,435 
Net (loss) profit attributable to:   -                     
The owners of the parent   4,256    4,017    1,421    7,251    2,457 
Non-controlling interest   (5)   (5)   (8)   (17)   (21)
                          
Earning per share attributable to owners of the parent                         
Basic   0.07    0.07    0.02    0.12    0.04 
Diluted   0.07    0.07    0.02    0.12    0.04 
                          
Weighted average basic shares outstanding   59,067    59,067    59,064    59,067    59,064 
Weighted average diluted shares outstanding   59,068    59,068    59,089    59,070    59,099 

 

 

 

 

Consolidated statements of comprehensive income (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In 000€  2023   2023   2022   2023   2022 
   U.S.$             
Net profit (loss) for the period   4,251    4,013    1,413    7,234    2,435 
Other comprehensive income                         
Recycling                         
Exchange difference on translation of foreign operations   (816)   (770)   225    471    1,291 
Non-recycling                         
Fair value adjustments through OCI - Equity instruments   -    -    -    -    - 
Other comprehensive income (loss), net of taxes   (816)   (770)   225    471    1,291 
Total comprehensive income (loss) for the year, net of taxes   3,435    3,242    1,638    7,705    3,726 
Total comprehensive income (loss) attributable to:                         
The owners of the parent   3,441    3,248    1,646    7,721    3,748 
Non-controlling interests   (6)   (5)   (8)   (15)   (21)

 

 

 

 

Consolidated statement of financial position (Unaudited)

 

   As of
September 30,
   As of
December 31,
 
In 000€  2023   2022 
Assets          
Non-current assets          
Goodwill   44,280    44,155 
Intangible assets   35,592    37,875 
Property, plant & equipment   94,399    94,276 
Right-of-Use assets   7,668    8,420 
Investments in joint ventures   -    - 
Deferred tax assets   2,031    1,186 
Investments in convertible loans   3,681    3,494 
Investments in non-listed equity instruments   307    307 
Other non-current assets   5,213    5,136 
Total non-current assets   193,170    194,847 
Current assets          
Inventories   16,764    16,081 
Trade receivables   41,998    51,043 
Other current assets   8,107    8,424 
Cash and cash equivalents   133,953    140,867 
Total current assets   200,821    216,414 
Total assets   393,991    411,262 

 

 

 

 

   As of
September 30,
   As of
December 31,
 
In 000€  2023   2022 
Equity and liabilities          
Equity          
Share capital   4,487    4,487 
Share premium   233,895    233,895 
Retained earnings and other reserves   (1,708)   (9,427)
Equity attributable to the owners of the parent   236,674    228,955 
Non-controlling interest   (43)   (28)
Total equity   236,631    228,928 
Non-current liabilities          
Loans & borrowings   45,204    55,873 
Lease liabilities   5,053    5,147 
Deferred tax liabilities   3,786    4,312 
Deferred income   8,533    9,277 
Other non-current liabilities   1,185    1,611 
Total non-current liabilities   63,761    76,220 
Current liabilities          
Loans & borrowings   13,491    17,058 
Lease liabilities   2,474    2,902 
Trade payables   20,799    23,230 
Tax payables   2,273    1,246 
Deferred income   37,940    41,721 
Other current liabilities   16,622    19,957 
Total current liabilities   93,599    106,114 
Total equity and liabilities   393,991    411,262 

 

 

 

 

Consolidated statement of cash flows (Unaudited)

 

   for the nine months ended
September 30,
 
In 000€  2023   2022 
Operating activities          
Net (loss) profit for the period   7,234    2,435 
Non-cash and operational adjustments          
Depreciation of property plant & equipment   11,162    11,335 
Amortization of intangible assets   5,046    4,859 
Impairment of goodwill and intangible assets   -    - 
Share-based payment expense   -    (121)
Loss (gain) on disposal of intangible assets and property, plant & equipment   (401)   59 
Movement in provisions   (434)   (506)
Movement reserve for bad debt and slow moving inventory   445    (42)
Financial income   (4,811)   (9,771)
Financial expense   3,389    5,009 
Impact of foreign currencies   (152)   98 
(Deferred) income taxes   892    1,384 
Working capital adjustments   (3,601)   9,109 
Decrease (increase) in trade receivables and other receivables   8,965    (184)
Decrease (increase) in inventories and contracts in progress   (751)   (4,356)
Increase (decrease) in deferred revenue   (4,532)   3,815 
Increase (decrease) in trade payables and other payables   (7,283)   9,834 
Income tax paid & Interest received   1,194    (262)
Net cash flow from operating activities   19,963    23,587 

 

 

 

 

   for the nine months ended
September 30,
 
In 000€  2023   2022 
Investing activities          
Purchase of property, plant & equipment   (6,862)   (16,066)
Purchase of intangible assets   (2,448)   (3,422)
Proceeds from the sale of property, plant & equipment & intangible assets (net)   645    319 
Acquisition of subsidiary (net of cash)   -    (29,355)
Net cash flow used in investing activities   (8,665)   (48,523)
Financing activities          
Repayment of loans & borrowings   (14,334)   (15,182)
Repayment of leases   (2,640)   (2,566)
Capital increase   -    - 
Interest paid   (1,334)   (1,665)
Other financial income (expense)   (25)   1,378 
Net cash flow from (used in) financing activities   (18,334)   (18,035)
Net increase/(decrease) of cash & cash equivalents   (7,037)   (42,972)
Cash & Cash equivalents at the beginning of the year   140,867    196,028 
Exchange rate differences on cash & cash equivalents   123    (2,433)
Cash & cash equivalents at end of the period   133,953    150,621 

 

 

 

 

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In 000€  2023   2022   2023   2022 
Net profit (loss) for the period   4,013    1,413    7,234    2,435 
Income taxes   (363)   478    886    1,377 
Financial expenses   1,554    2,110    3,599    4,671 
Financial income   (2,873)   (4,283)   (4,987)   (9,800)
Depreciation and amortization   5,527    5,378    16,191    16,194 
EBITDA   7,857    5,096    22,923    14,876 
Share-based compensation expense (1)   -    (24)   -    (121)
Adjusted EBITDA   7,857    5,072    22,923    14,755 

 

(1) Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

 

 

 

 

Segment P&L (Unaudited)

 

In 000€  Materialise
Software
   Materialise
Medical
   Materialise
Manufacturing
   Total
segments
   Unallocated (1)   Consolidated 
For the three months ended September 30, 2023                              
Revenues   10,811    24,263    25,056    60,130    0    60,130 
Segment (adj) EBITDA   1,781    7,143    1,074    9,998    (2,141)   7,857 
Segment (adj) EBITDA %   16.5%   29.4%   4.3%   16.6%        13.1%
For the three months ended September 30, 2022                              
Revenues   10,863    21,391    26,033    58,288    0    58,288 
Segment (adj) EBITDA   202    4,765    2,530    7,497    (2,425)   5,072 
Segment (adj) EBITDA %   1.9%   22.3%   9.7%   12.9%        8.7%

 

In 000€  Materialise
Software
   Materialise
Medical
   Materialise
Manufacturing
   Total
segments
   Unallocated (1)   Consolidated 
For the nine months ended September 30, 2023                              
Revenues   33,192    73,528    84,112    190,832    0    190,832 
Segment (adj) EBITDA   6,190    17,179    6,980    30,349    (7,426)   22,923 
Segment (adj) EBITDA %   18.7%   23.4%   8.3%   15.9%        12.0%
For the nine months ended September 30, 2022                              
Revenues   31,989    60,592    76,739    169,319    0    169,319 
Segment (adj) EBITDA   2,955    12,466    6,722    22,144    (7,388)   14,755 
Segment (adj) EBITDA %   9.2%   20.6%   8.8%   13.1%        8.7%

 

(1)  Unallocated segment adjusted EBITDA consists of corporate research and development and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA.

 

 

 

 

Reconciliation of Net Profit (Loss) to Segment adjusted EBITDA (Unaudited)

 

   for the three months ended
September 30,
   for the nine months ended
September 30,
 
In 000€  2023   2022   2023   2022 
Net profit (loss) for the period   4,013    1,413    7,234    2,435 
Income taxes   (363)   478    886    1,377 
Financial cost   1,554    2,110    3,599    4,671 
Financial income   (2,873)   (4,283)   (4,987)   (9,800)
Operating (loss) profit   2,330    (282)   6,732    (1,318)
Depreciation and amortization   5,527    5,378    16,191    16,194 
Corporate research and development   604    592    2,063    2,057 
Corporate headquarter costs   2,399    2,491    7,636    7,103 
Other operating income (expense)   (862)   (681)   (2,274)   (1,892)
Segment adjusted EBITDA   9,998    7,497    30,349    22,144 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MATERIALISE NV
     
  By:  

/s/ Wilfried Vancraen

  Name:   Wilfried Vancraen
  Title:   Chief Executive Officer

 

Date: October 26, 2023